These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38530942)

  • 1. Important Radiologic and Clinical Factors for Predicting Overall Survival in Pancreatic Adenocarcinoma Patients Who Underwent FOLFIRINOX.
    Park SJ; Kim JH; Choi SY; Joo I
    Pancreas; 2024 Aug; 53(7):e553-e559. PubMed ID: 38530942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT.
    Park SJ; Kim JH; Joo I; Han JK
    Abdom Radiol (NY); 2021 Oct; 46(10):4765-4778. PubMed ID: 34085090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Important CT and histopathological findings for recurrence and overall survival in patients with pancreatic ductal adenocarcinoma who underwent surgery after neoadjuvant FOLFIRINOX.
    Park SJ; Kim JH; Joo I; Lee KB; Han JK
    Eur Radiol; 2021 Jun; 31(6):3616-3626. PubMed ID: 33201279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma.
    Ulusakarya A; Teyar N; Karaboué A; Haydar M; Krimi S; Biondani P; Gumus Y; Chebib A; Almohamad W; Morère JF
    Medicine (Baltimore); 2019 Apr; 98(16):e15341. PubMed ID: 31008993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
    Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
    Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms.
    Brada LJH; Walma MS; Daamen LA; van Roessel S; van Dam RM; de Hingh IH; Liem MLS; de Meijer VE; Patijn GA; Festen S; Stommel MWJ; Bosscha K; Polée MB; Yung Nio C; Wessels FJ; de Vries JJJ; van Lienden KP; Bruijnen RC; Los M; Mohammad NH; Wilmink HW; Busch OR; Besselink MG; Quintus Molenaar I; van Santvoort HC;
    J Surg Oncol; 2021 Sep; 124(4):589-597. PubMed ID: 34115379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.
    Cecchini M; Salem RR; Robert M; Czerniak S; Blaha O; Zelterman D; Rajaei M; Townsend JP; Cai G; Chowdhury S; Yugawa D; Tseng R; Mejia Arbelaez C; Jiao J; Shroyer K; Thumar J; Kortmansky J; Zaheer W; Fischbach N; Persico J; Stein S; Khan SA; Cha C; Billingsley KG; Kunstman JW; Johung KL; Wiess C; Muzumdar MD; Spickard E; Aushev VN; Laliotis G; Jurdi A; Liu MC; Escobar-Hoyos L; Lacy J
    JAMA Oncol; 2024 Aug; 10(8):1027-1035. PubMed ID: 38900452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
    Bonnet E; Mastier C; Lardy-Cléaud A; Rochefort P; Sarabi M; Guibert P; Cattey-Javouhey A; Desseigne F; de La Fouchardière C
    Curr Oncol; 2019 Aug; 26(4):e466-e472. PubMed ID: 31548814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
    Shibuki T; Mizuta T; Shimokawa M; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Makiyama A; Taguchi H; Honda T; Mitsugi K; Nio K; Ide Y; Ureshino N; Shirakawa T; Otsuka T
    BMC Cancer; 2022 Jan; 22(1):19. PubMed ID: 34980029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.
    Chevalier H; Vienot A; Lièvre A; Edeline J; El Hajbi F; Peugniez C; Vernerey D; Meurisse A; Hammel P; Neuzillet C; Borg C; Turpin A
    Oncologist; 2020 Nov; 25(11):e1701-e1710. PubMed ID: 32886823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
    Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
    JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma.
    Laurent-Badr Q; Barbe C; Brugel M; Hautefeuille V; Volet J; Grelet S; Desot E; Botsen D; Deguelte S; Pitta A; Abdelli N; Brasseur M; De Mestier L; Neuzillet C; Bouché O
    Dig Liver Dis; 2020 Jun; 52(6):658-667. PubMed ID: 32362489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
    Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
    Baron MK; Wang X; Nevala-Plagemann C; Moser JC; Haaland B; Garrido-Laguna I
    Pancreas; 2021 Jul; 50(6):796-802. PubMed ID: 34347727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan.
    Fornaro L; Leone F; Vienot A; Casadei-Gardini A; Vivaldi C; Lièvre A; Lombardi P; De Luca E; Vernerey D; Sperti E; Musettini G; Satolli MA; Edeline J; Spadi R; Neuzillet C; Falcone A; Pasquini G; Clerico M; Passardi A; Buscaglia P; Meurisse A; Aglietta M; Brac C; Vasile E; Montagnani F
    Clin Colorectal Cancer; 2019 Dec; 18(4):e394-e401. PubMed ID: 31564556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
    Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
    Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.